Officials said the site was shut down. “Due to extreme caution” after some people had adverse reactions to Johnson & Johnson / Janssen images.
DENVER, Colorado – Vaccine-appointed people were abstained from numerous vaccination sites at Dick’s Sporting Goods Park after some on-site Johnson & Johnson vaccine recipients experienced adverse reactions, according to a Centura Health spokesperson.
Of the more than 1,700 people vaccinated at the site on Wednesday, Centura Health said 0.8%, or about 13 people, had an adverse reaction.
Officials said appointments were postponed for the rest of the day as a precaution while they reviewed.
“After receiving the J&J vaccine and during off-site observations, we discovered a limited number of adverse reactions from the vaccine,” a Centura Health statement read.
About 640 people were involved, Centura Health said and would be automatically postponed for another vaccine clinic on Sunday, April 11, Centura Health said.
> Video above from March 28: Some people have to wait 3 hours at one of Colorado’s many vaccination sites.
Related: Some Experience Waiting 3 Hours at a Denver Vaccination Location on Sunday
In the first weekend of operation starting on March 27, many vaccination sites in Commerce City have suffered heavy traffic jams and frustrated people.
Some people told 9NEWS they waited in line for up to three hours on Sunday at the mass vaccination facility at Dick’s Sporting Goods Park.
People registered for the vaccine at the site are told to wait 15 to 30 minutes.
Centura Health, which operates the site, told COVIDCheck Colorado partner 9NEWS that it was “unable to secure adequate staff safety to accommodate increased vaccine volumes”.
“[COVIDCheck Colorado] “Centura Health has adjusted their resources and is working swiftly to improve wait times,” Centura Health said in a statement. First drug “
Related: Emergent BioSolutions, Maryland-based Company That Must Ditch J&J 15M Vaccine, Has a History of Abuse
Johnson & Johnson said on Wednesday that a batch of vaccines made by Emergent BioSolutions could not be used at a facility in Baltimore known as Bayview because it did not meet quality standards. It is unclear how the issues will affect future J & J’s vaccine deliveries, the company said in a statement that it still plans to deliver 100 million doses by the end of June and “Aim to deliver those volumes by the end of May”
The company at the center of the quality issue that forced Johnson & Johnson to ditch 15 million doses of the coronavirus has cited US health officials on quality control issues.
Emergent BioSolutions, a lesser-known company critical to the vaccine supply chain, is key in Johnson & Johnson’s plan to deliver 100 million single-shot vaccines to the United States by the end of May. But the Food and Drug Administration has cited several emergency issues such as poorly trained workers, broken bottles and problems handling mold and other contamination around one of the factories, according to records. Obtained by The Associated Press through the Freedom of Information Act. The record covers inspections in emergency sites since 2017.
Recommended video: COVID-19 vaccine